Bacillus subtilis Monitor: November 2026
A monthly digest for pharmacists, therapists and doctors on new science around Bacillus subtilis, spore-forming probiotics and silicon, with a regional lens on EU/CEE, MENA and Africa. November 2026.
New clinical results
Six recent human studies show the field moving from single symptoms to strain-specific, placebo-controlled trials. Most are small and industry-funded, so read them as signals, not proof.
Children with antibiotic-associated diarrhoea, India. In a double-blind trial in 68 children aged 1–12, B. subtilis HU58 (2 × 10⁹ CFU/day for 7 days) given after diarrhoea began was linked to faster return to normal stools by day 3 than placebo. Small, one country, short follow-up. Sorensen et al., Beneficial Microbes 2025
Adults with diarrhoea-predominant IBS, India. A 4-week pilot in 61 adults found a B. subtilis HU58 + Heyndrickxia faecalis SC208 blend improved abdominal pain and stool consistency versus placebo; perceived stress did not change. Pilot size, multi-strain product. Sorensen et al., Beneficial Microbes 2026
Functional bloating, healthy adults. In 100 adults, B. subtilis ATCC 122264 (5 × 10⁹ CFU/day, 8 weeks) did not beat placebo on the main gas-symptom score; a sub-group of women reported less belching and flatulence. Negative primary results get published too. LeMoire et al., Beneficial Microbes 2025
Carotenoid status, premenopausal women. Adding B. subtilis Rosell-179 to a carotenoid supplement for 10 weeks gave a slightly larger rise in skin carotenoid score than placebo, just short of statistical significance (P = 0.056), with no change in skin hydration or wrinkles. A good example of a modest result. Roldos et al., Journal of Nutrition 2026
Paediatric functional constipation, Vietnam. In 111 children aged 2–5, two multi-strain Bacillus spore products (including B. subtilis) for 28 days reduced the share of children with constipation 3.7- to 5.1-fold versus placebo, with shifts in gut microbiota and immune markers. Manufacturer-linked trial. Nguyen et al., Communications Medicine 2026
Meta-analysis, H. pylori therapy. Pooling 26 trials (3,536 patients), adding live combined B. subtilis + Enterococcus faecium to H. pylori treatment was associated with higher eradication and fewer side effects; almost all included trials were from China. Yang et al., Clinics 2026
All effects are strain- and product-specific. None of these studies tested MM40® (DSM 21097).
Trials to watch: EU/CEE, MENA and Africa
Three registered studies that include Bacillus subtilis or its gut context are running in our regions now; results are expected in 2027.
EU, France: SUBTILE (NCT07212907), Biocodex, CHU Rouen and primary care. Spore-formers B. coagulans MY01 + B. subtilis MY02 with ginger extract in functional dyspepsia, 8 weeks. 198 adults, recruiting. Expected January 2027.
MENA / Africa, Egypt: NCT07845669, Alexandria University. Multispecies synbiotic (includes B. subtilis) after autologous bone-marrow transplant: GI symptoms, appetite, nutrition. 40 adults, not yet recruiting. Expected end 2027.
CEE, Poland: SUPRIMDIET (NCT07793487), Warsaw University of Life Sciences. Fermented milk with Levilactobacillus brevis B1 in IBS and metabolic syndrome. 80 adults, enrolling. Expected September 2027. Listed as a CEE gut-health trial to follow; it does not use B. subtilis.
Interesting facts
B. subtilis from newborns. Researchers in India isolated B. subtilis strains from neonatal meconium and screened them for acid and bile tolerance, gut-cell adhesion and safety in the lab: a reminder that the species is a natural part of the human gut, not only of soil and fermented food. Lab data only. Singh et al., Frontiers in Microbiology 2026
Heat-killed can matter too. A Japanese trial in 112 adults reported better mood scores with heat-inactivated B. subtilis natto (strain QOL) over 8 weeks: the "postbiotic" angle. Nakamura et al., Functional Foods in Health and Disease 2025
One review, three mechanisms. A 2026 review of 115 studies groups B. subtilis and B. natto effects into digestive enzymes, mucosal immunity and microbiota-metabolism links. Hua et al., Nutrients 2026
Longevity and the gut–brain axis
In a mouse model of inflammation-driven memory loss, B. subtilis, but not a lactobacilli mix, preserved spatial memory, lowered brain inflammation markers and restored gut microbial diversity. Animal data only, but it fits the growing interest in the gut–brain axis in ageing. Murgina et al., Brain Sciences 2026
Silicon corner (silicium)
Silicon research in 2025–26 shows promising signals for bone, connective tissue and vessels, but still few controlled human trials, and results depend heavily on the silicon form.
Vessels and healthy ageing, France. In a 6-month double-blind trial in 120 healthy adults aged 60–75, silicon-enriched spirulina showed no effect in the whole group; in the sub-group with high-normal blood pressure and stiff arteries, blood pressure fell 8% and pulse-wave velocity 13.5%. Sub-group finding, to be confirmed. Virsolvy et al., Nutrients 2025
Bone healing after dental implants. In 28 smokers, choline-stabilised orthosilicic acid for one month after implant surgery was linked to higher bone-formation markers and less crestal bone loss than vitamins C + E. Very small, no placebo arm. Gupta et al., International Journal of Clinical Trials 2026
Brittle nails: what the evidence supports. A 2026 review finds biotin has the most studies, while stabilised orthosilicic acid (~10 mg silicon/day) has the better-controlled trial; overall evidence is limited. de Carvalho et al., 2026
Form matters. A review of orthosilicic acid (the bioavailable form) covers stabilised delivery systems and proposes a "bone–vascular–immune axis" as a research framework. Pan et al., Critical Reviews in Food Science and Nutrition 2026
The sober view. A critical review of lithium, silicon and boron concludes human data are still too limited for dietary recommendations; silicon's evidence rests mainly on bone-related observational studies. Melenikioti et al., Nutrients 2026
Fracture healing, animal study, Turkey. In rats, an arginine-silicate-inositol complex improved callus formation and bone healing in a dose-dependent way. Animal data only. Demir et al., Biological Trace Element Research 2026
Silicon has no EU-authorised health claim; these summaries describe research only.
Events
9–11 February 2027: IPA World Congress + Probiota 2027, Berlin, Germany (Estrel Berlin). Industry and science.
22–24 June 2027: International Probiotics Conference (IPC) 2027, Kraków, Poland. Scientific programme on probiotics, prebiotics and gut microbiota.
17–18 October 2026 (held): MENA Microbiome 2026, Sidra Medicine, Doha, Qatar. Second edition; the 2027 edition is not yet announced.
Africa: no dedicated microbiome congress for 2027 confirmed yet; we will check before the December issue.
About this digest
The Monitor reports science; it never sells. Summaries are in our own words, with population, dose, duration, result and limits. Peer-reviewed papers and registered trials come first; animal and lab studies are labelled as such.
This digest summarises published research for healthcare professionals. It is not medical advice and makes no claims about any product. Results apply to the strains and conditions studied only.
Comments